PHAT Q3'26 Earnings: EPS estimate is (0.11) USD

What happened

Phathom Pharmaceuticals is set to announce its Q3'26 results on October 29 before the market opens. The revenue estimate is 84.82 million USD and the EPS estimate is (0.11) USD, meaning a loss per share.

Confirmed

Global impact / market context

A loss per share estimate means analysts expect costs to exceed profit on each share. Revenue is expected at 84.82 million USD, so investors will compare actual sales against that figure to judge whether the company's growth trend is continuing.

Analyst inference

Revenue estimates have risen each quarter in the supplied data, and reported revenue beat estimates in four listed quarters. The Q3'26 estimate of 84.82 million USD is above the prior quarter's reported figure, implying expectations of continued growth.

Analyst inference

What to watch

1. The actual Q3'26 revenue result versus the 84.82 million USD estimate, since reported revenue has beaten estimates in the supplied quarterly records. Confirmed
2. The company's forward guidance on future revenue and spending, which could shape investor expectations for whether the current growth trend continues into later quarters. Proposed
3. Whether the reported loss per share is narrower or wider than the (0.11) USD estimate, since past EPS surprises have varied between positive and negative outcomes. Analyst inference

Evidence

• Original source link unavailable